To print this article, all you need is to be registered or login on Mondaq.com.
On December 24, 2020, the Federal Court issued a decision in a
patent infringement action pursuant to s. 6(1) of the
Patented
Medicines (Notice of Compliance) Regulations relating to
silodosin (Allergan s
RAPAFLO):
Allergan Inc v Sandoz Canada
Inc, 2020 FC 1189. Chief Justice Crampton found
that Canadian Patent No. 2,507,002, relating to a capsule formulation
of silodosin, is not invalid on the basis of obviousness but not
infringed as the Sandoz Product does not contain granules and does not involve granulating or a wet granulation process , all of which were found to